Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension and Interstitial Lung Disease
NCT03814317Phase 2Completed
- Sponsor
- University of Florida
- Start
- Jan 2020
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treprostinil in pulmonary hypertension (PH), sponsored by University of Florida. Primary endpoints: Pulmonary Vascular Resistance at Week 16 and Mean Pulmonary Arterial Pressure at Week 16. Started Jan 2020; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03814317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814317.